Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study
- Resource Type
- Article
- Source
- The Lancet HIV; December 2017, Vol. 4 Issue: 12 pe536-e546, 11p
- Subject
- Language
- ISSN
- 24054704; 23523018